281 related articles for article (PubMed ID: 30338051)
1. The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications.
Cavalcanti MS; Gönen M; Klimstra DS
Int J Endocr Oncol; 2016 Aug; 3(3):203-219. PubMed ID: 30338051
[TBL] [Abstract][Full Text] [Related]
2. [Gastroenteropancreatic neuroendocrine tumors: what must the pathologist know and do in 2014?].
Scoazec JY; Couvelard A;
Ann Pathol; 2014 Feb; 34(1):40-50. PubMed ID: 24630636
[TBL] [Abstract][Full Text] [Related]
3. [Consensus and controversy on subtype classification of gastric neuroendocrine neoplasms].
Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):977-981. PubMed ID: 28900986
[TBL] [Abstract][Full Text] [Related]
4. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters.
Niederle MB; Hackl M; Kaserer K; Niederle B
Endocr Relat Cancer; 2010 Dec; 17(4):909-18. PubMed ID: 20702725
[TBL] [Abstract][Full Text] [Related]
5. Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors.
Liu TC; Hamilton N; Hawkins W; Gao F; Cao D
Am J Surg Pathol; 2013 Jun; 37(6):853-9. PubMed ID: 23598967
[TBL] [Abstract][Full Text] [Related]
6. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
Klöppel G
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine neoplasms of the gastroenteropancreatic system: pathology and classification.
Anlauf M
Horm Metab Res; 2011 Nov; 43(12):825-31. PubMed ID: 22105474
[TBL] [Abstract][Full Text] [Related]
8. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.
Klöppel G; Rindi G; Anlauf M; Perren A; Komminoth P
Virchows Arch; 2007 Aug; 451 Suppl 1():S9-27. PubMed ID: 17684761
[TBL] [Abstract][Full Text] [Related]
9. Comparison of WHO 2000 and WHO 2010 classifications of gastroenteropancreatic neuroendocrine tumors.
Karakuş E; Helvacı A; Ekinci O; Dursun A
Turk J Gastroenterol; 2014 Feb; 25(1):81-7. PubMed ID: 24918137
[TBL] [Abstract][Full Text] [Related]
10. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
[TBL] [Abstract][Full Text] [Related]
11. The expression of NeuroD and mASH1 in the gastroenteropancreatic neuroendocrine tumors.
Shida T; Furuya M; Kishimoto T; Nikaido T; Tanizawa T; Koda K; Oda K; Takano S; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Nakatani Y; Miyazaki M
Mod Pathol; 2008 Nov; 21(11):1363-70. PubMed ID: 18587321
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the prognostic values of the 2010 WHO classification, AJCC 7th edition, and ENETS classification of gastric neuroendocrine tumors.
Kim BS; Park YS; Yook JH; Kim BS
Medicine (Baltimore); 2016 Jul; 95(30):e3977. PubMed ID: 27472674
[TBL] [Abstract][Full Text] [Related]
13. The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond.
Sorbye H; Baudin E; Perren A
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):683-698. PubMed ID: 30098724
[TBL] [Abstract][Full Text] [Related]
14. [Interpretation of updated international guidelines for diagnosis and treatment of gastroenter-opancreatic neuroendocrine neoplasms].
Chen LH; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Oct; 24(10):843-848. PubMed ID: 34674457
[TBL] [Abstract][Full Text] [Related]
15. Gastroenteropancreatic neuroendocrine neoplasms: selected pathology review and molecular updates.
Chai SM; Brown IS; Kumarasinghe MP
Histopathology; 2018 Jan; 72(1):153-167. PubMed ID: 29239038
[TBL] [Abstract][Full Text] [Related]
16. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
Klöppel G
Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
[TBL] [Abstract][Full Text] [Related]
17. ENETS standardized (synoptic) reporting for neuroendocrine tumour pathology.
van Velthuysen MF; Couvelard A; Rindi G; Fazio N; Hörsch D; Nieveen van Dijkum EJ; Klöppel G; Perren A
J Neuroendocrinol; 2022 Mar; 34(3):e13100. PubMed ID: 35165954
[TBL] [Abstract][Full Text] [Related]
18. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors.
Shida T; Kishimoto T; Furuya M; Nikaido T; Koda K; Takano S; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Tanizawa T; Nakatani Y; Miyazaki M
Cancer Chemother Pharmacol; 2010 Apr; 65(5):889-93. PubMed ID: 19657638
[TBL] [Abstract][Full Text] [Related]
19. Gastroenteric neuroendocrine neoplasms classification: comparison of prognostic models.
Dolcetta-Capuzzo A; Villa V; Albarello L; Franchi GM; Gemma M; Scavini M; Di Palo S; Orsenigo E; Bosi E; Doglioni C; Manzoni MF
Cancer; 2013 Jan; 119(1):36-44. PubMed ID: 22744914
[TBL] [Abstract][Full Text] [Related]
20. Gastroenteropancreatic neuroendocrine neoplasms: historical context and current issues.
Yang Z; Tang LH; Klimstra DS
Semin Diagn Pathol; 2013 Aug; 30(3):186-96. PubMed ID: 24144288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
